Median PFS, months
Pmab + FOLFOX
FOLFOX
HR (95% CI)
Left
12.9
9.2
0.72 (0.57‒0.90)
Right
7.5
7.0
0.80 (0.50‒1.26)
Panitumumab outcome by tumour location analysis
PRIME study: PFS
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
68
64
60
56
52
48
44
40
36
32
28
24
20
16
12
8
4
0
0
20
40
60
80
100
Kaplan–Meier estimate
Months
0
1
0
1
1
0
1
1
2
2
1
4
2
1
11
5
1
0
15
9
1
1
22
10
1
1
28
15
3
2
34
20
6
2
45
24
6
4
59
33
6
6
85
50
9
11
111
81
17
18
146
127
31
34
169
159
39
49
1:
2:
3:
4:
No. of subjects
3: Pmab + FOLFOX right side
1: Pmab + FOLFOX left side
2: FOLFOX left side
4: FOLFOX right side
WT
RAS
